Feb 20 (Reuters) - Xenon Pharmaceuticals Inc (XENE.O) :
* XENON PHARMACEUTICALS ADVANCES SECOND PROPRIETARY EPILEPSY PRODUCT INTO THE CLINIC WITHINITIATION OF XEN901 PHASE 1 CLINICAL TRIAL
Source text for Eikon: Further company coverage: (XENE.O)
BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.